Companies › BeiGene
6 active drug programs in 19 registered trials: 9 Phase 2, 7 Phase 1, 3 Phase 3; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tislelizumab (A317) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Non Small Cell Lung Cancer; Urothelial Carcinoma; Non-small Cell Lung Cancer; MSI-H/dMMR Solid Tumors … | Nov 2026 |
| Pamiparib (BGB-290) Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor | PARP1, PARP2 | Phase 3 | Ovarian Cancer; Locally Advanced Prostate Cancer; Head and Neck Cancer; Glioblastoma | Jan 2027 |
| Alcestobart (LBL-007) | – | Phase 2 | Non-small Cell Lung Cancer; Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | Dec 2026 |
| BGB-11417 (sonrotoclax) BCL2 inhibitor | BCL2 | Phase 2 | Leukemia; MCL; Chronic Lymphocytic Leukemia (CLL) | Aug 2027 |
| BGB-A445 anti-NECTIN4 antibody-drug conjugate | NECTIN4 | Phase 2 | Non-small Cell Lung Cancer; Urothelial Carcinoma | – |
| BG-68501 Cyclin-dependent kinase-2 inhibitor | CDK2 | Phase 1 | Breast Cancer | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05661955 | Tislelizumab (A317) | Phase 1 | Urothelial Carcinoma | Oncology | May 2025 |
| NCT05661955 | BGB-A445 | Phase 1 | Urothelial Carcinoma | Oncology | May 2025 |
| NCT05635708 | Alcestobart (LBL-007) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT05635708 | Tislelizumab (A317) | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT05635708 | BGB-A445 | Phase 2 | Non-small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT03736889 | Tislelizumab (A317) | Phase 2 | MSI-H/dMMR Solid Tumors | Oncology | Nov 2026 |
| NCT05609370 | Alcestobart (LBL-007) | Phase 1 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | Oncology | Dec 2026 |
| NCT05609370 | Tislelizumab (A317) | Phase 1 | Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer | Oncology | Dec 2026 |
| NCT03519230 | Pamiparib (BGB-290) | Phase 3 | Ovarian Cancer | Oncology | Jan 2027 |
| NCT05652283 | Pamiparib (BGB-290) | Phase 2 | Ovarian Cancer | Oncology | Mar 2027 |
| NCT04379635 | Tislelizumab (A317) | Phase 3 | Non Small Cell Lung Cancer | Oncology | Mar 2027 |
| NCT03967977 | Tislelizumab (A317) | Phase 3 | Urothelial Carcinoma | Oncology | Jun 2027 |
| NCT05479994 | BGB-11417 (sonrotoclax) | Phase 2 | Leukemia | Oncology | Aug 2027 |
| NCT06257264 | BG-68501 | Phase 1 | Breast Cancer | Oncology | Aug 2027 |
| NCT05526924 | Pamiparib (BGB-290) | Phase 1 | Head and Neck Cancer | Oncology | Jan 2028 |
| NCT06463691 | BGB-11417 (sonrotoclax) | Phase 2 | MCL | Oncology | Dec 2028 |
| NCT06387056 | Pamiparib (BGB-290) | Phase 2 | Locally Advanced Prostate Cancer | Oncology | Apr 2029 |
| NCT03749187 | Pamiparib (BGB-290) | Phase 1 | Glioblastoma | Oncology | Jul 2029 |
| NCT07508995 | BGB-11417 (sonrotoclax) | Phase 2 | Chronic Lymphocytic Leukemia (CLL) | Oncology | Jul 2031 |
AstraZeneca Akeso Merck & Co. (MSD) Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group AbbVie Ascentage Pharma Group BeOne Medicines Pfizer GSK
CSPC Megalith Biopharmaceutical Lepu Biopharma Chipscreen Biosciences Akeso Arcus Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.